Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients
Mario Karolyi, Erich Pawelka, Theresa Mader, Sara Omid, H. Kelani, Sarah Ely, Bernd Jilma, Sebastian Baumgartner, Hermann Laferl, Clemens Ott, Marianna Traugott, Michael Turner, Tamara Seitz, Christoph Wenisch, Alexander Zoufaly
Topics & Concepts
MedicineLopinavirHydroxychloroquineRitonavirDiscontinuationInternal medicineLopinavir/ritonavirIntensive care unitGastroenterologyCoronavirus disease 2019 (COVID-19)Viral loadHuman immunodeficiency virus (HIV)DiseaseImmunologyAntiretroviral therapyInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19